{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:06:35Z","timestamp":1770908795678,"version":"3.50.1"},"reference-count":168,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Translation"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.4161\/trla.28968","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T16:18:39Z","timestamp":1398788319000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Targeting translation initiation in breast cancer"],"prefix":"10.1080","volume":"2","author":[{"given":"Argun","family":"Akcakanat","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics; Houston, TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics; Houston, TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics; Houston, TX USA"},{"name":"Department of Surgical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"American Cancer Society. Cancer Facts and Figures 2013. Atlanta GA: American Cancer Society 2013."},{"key":"e_1_3_3_3_1","first-page":"971","article-title":"Translation initiation in cancer: a novel target for therapy","volume":"1","author":"Meric F","year":"2002","unstructured":"Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 2002; 1:971 - 9; PMID: 12481419","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2824"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0026"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.218"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012336"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.042"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.68.1.913"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.16"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2303"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80122-7"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0766"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.241"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0116-7"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Li BD McDonald JC Nassar R De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998; 227:756-6l; discussion 61-3.","DOI":"10.1097\/00000658-199805000-00016"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a013706"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1130276"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.16.4370"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)54634-2"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.11.041"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9525(00)02106-5"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402727200"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3732"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.02-02-0017"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)01025-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203765"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3343"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41680"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M606284200"},{"key":"e_1_3_3_31_1","first-page":"988","article-title":"Cloning of a novel protein overexpressed in human mammary carcinoma","volume":"57","author":"Bachmann F","year":"1997","unstructured":"Bachmann F, B\u00e4nziger R, Burger MM. Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res 1997; 57:988 - 94; PMID: 9041205","journal-title":"Cancer Res"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2591"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E02-12-0784"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207465"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64797-9"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl021"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65433-8"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209495"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605418200"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204624"},{"key":"e_1_3_3_41_1","first-page":"175","article-title":"Reduced expression of INT-6\/eIF3-p48 in human tumors","volume":"18","author":"Marchetti A","year":"2001","unstructured":"Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Callahan R. Reduced expression of INT-6\/eIF3-p48 in human tumors. Int J Oncol 2001; 18:175 - 9; PMID: 11115556","journal-title":"Int J Oncol"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M800493-MCP200"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.371"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.11.11.4005"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.152"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.10.3.1134-1144.1990"},{"key":"e_1_3_3_47_1","first-page":"2489","article-title":"Enhanced expression of translation factor mRNAs in hepatocellular carcinoma","volume":"20","author":"Shuda M","year":"2000","unstructured":"Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 2000; 20:2489 - 94; PMID: 10953316","journal-title":"Anticancer Res"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207713"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2761"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.236"},{"key":"e_1_3_3_52_1","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau ME","year":"2008","unstructured":"Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA Jr., et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118:2651 - 60; PMID: 18551192","journal-title":"J Clin Invest"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-175430"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110846"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.3.1871"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.24.14597"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.05.024"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207545"},{"key":"e_1_3_3_59_1","first-page":"1343","article-title":"Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis","volume":"20","author":"Zimmer SG","year":"2000","unstructured":"Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20:3A 1343 - 51; PMID: 10928042","journal-title":"Anticancer Res"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200707018"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208821200"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53649-8"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.36.21176"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0530"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303781110"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0752"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1042"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0420"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200205000-00016"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.sla.0000184224.55949.90","article-title":"A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer","volume":"242","author":"McClusky DR","year":"2005","unstructured":"McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005; 242:584 - 90, discussion 590-2; PMID: 16192819","journal-title":"Ann Surg"},{"key":"e_1_3_3_71_1","doi-asserted-by":"crossref","unstructured":"Holm N Byrnes K Johnson L Abreo F Sehon K Alley J Meschonat C Md QC Li BD. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer. Ann Surg Oncol 2008.","DOI":"10.1245\/s10434-008-0086-9"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2009.05.010"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2009.03.060"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3472"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605044"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.10.019"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.492371"},{"key":"e_1_3_3_78_1","first-page":"5041","article-title":"Malignant transformation by overproduction of translation initiation factor eIF4G","volume":"57","author":"Fukuchi-Shimogori T","year":"1997","unstructured":"Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 1997; 57:5041 - 4; PMID: 9371500","journal-title":"Cancer Res"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200710215"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1900"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1877-1173(09)90002-3"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1554"},{"key":"e_1_3_3_83_1","first-page":"6894","article-title":"Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines","volume":"63","author":"Arora S","year":"2003","unstructured":"Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, Ortiz PA, Hait WN. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res 2003; 63:6894 - 9; PMID: 14583488","journal-title":"Cancer Res"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2"},{"key":"e_1_3_3_85_1","first-page":"1181","article-title":"Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2\/M progression in the cell cycle","volume":"34","author":"Nakamura J","year":"2009","unstructured":"Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, Fukuda M, Yamamoto Y, Fukuda I, Tatsumi N, et al. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2\/M progression in the cell cycle. Int J Oncol 2009; 34:1181 - 9; PMID: 19360331","journal-title":"Int J Oncol"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2889"},{"key":"e_1_3_3_87_1","first-page":"2260","article-title":"Phosphorylation of elongation factor 2 in normal and malignant rat glial cells","volume":"53","author":"Bagaglio DM","year":"1993","unstructured":"Bagaglio DM, Cheng EH, Gorelick FS, Mitsui K, Nairn AC, Hait WN. Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res 1993; 53:Suppl 2260 - 4; PMID: 8485712","journal-title":"Cancer Res"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4036"},{"key":"e_1_3_3_89_1","first-page":"615","article-title":"Calmodulin-dependent protein kinases in rat glioblastoma","volume":"6","author":"Cheng EH","year":"1995","unstructured":"Cheng EH, Gorelick FS, Czernik AJ, Bagaglio DM, Hait WN. Calmodulin-dependent protein kinases in rat glioblastoma. Cell Growth Differ 1995; 6:615 - 21; PMID: 7647041","journal-title":"Cell Growth Differ"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690012"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041171"},{"key":"e_1_3_3_92_1","first-page":"1387","article-title":"Alterations in the expression of PDCD4 in ductal carcinoma of the breast","volume":"18","author":"Wen YH","year":"2007","unstructured":"Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 2007; 18:1387 - 93; PMID: 17982621","journal-title":"Oncol Rep"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204137"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.1.26-37.2003"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1719"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385114-7.00019-2"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385928-0.00003-1"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.09.006"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1115079"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406927102"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2357"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32044"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0430"},{"key":"e_1_3_3_104_1","unstructured":"Pharmaceuticals I. Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01234038 NLM identifier: NCT1234038."},{"key":"e_1_3_3_105_1","unstructured":"Pharmaceuticals I. Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01234025 NLM identifier: NCT01234025."},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb9000475"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205153"},{"key":"e_1_3_3_108_1","doi-asserted-by":"crossref","first-page":"E315","DOI":"10.25011\/cim.v34i6.15889","article-title":"Targeting the oncogene eIF4E in cancer: From the bench to clinical trials","volume":"34","author":"Borden KL","year":"2011","unstructured":"Borden KL. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials. Clin Invest Med 2011; 34:E315; PMID: 22129918","journal-title":"Clin Invest Med"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.57"},{"key":"e_1_3_3_110_1","unstructured":"Jewish General Hospital. A Phase I\/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes and AML With High eIF4E Expression. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01056523 NLM identifier: NCT01056523."},{"key":"e_1_3_3_111_1","unstructured":"Jewish General Hospital. A Phase I\/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01056757 NLM identifier: NCT01056757."},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.2132505"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.2930805"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)00567-4"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01716"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2924"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.11.046"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011477108"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504249102"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.10.005"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-1026"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005223"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio776"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.12.025"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(95)00165-4"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10515"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25255"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.1351"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209965"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00582.x"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6487"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)10662-7"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1977.tb11256.x"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.04.005"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795049778"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2009.01.004"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0361"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3033"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2402"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.0708"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8391"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.49"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.3331"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4322"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167940"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1385"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb839"},{"key":"e_1_3_3_154_1","unstructured":"National Cancer Institute. Phase II Trial of Akt Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation or an AKT Mutation and\/or PTEN Loss\/PTEN Mutation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01277757 NLM identifier: NCT01277757."},{"key":"e_1_3_3_155_1","unstructured":"QuantumLeap Healthcare Collaborative. I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009- [cited 2014 March 27]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01042379 NLM identifier: NCT01042379."},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34739;"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2008.07.078"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.159046"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.7.12965"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3298"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-0310"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.19.6410"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.6.7933"},{"key":"e_1_3_3_165_1","first-page":"1627","article-title":"Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro","volume":"32","author":"Liu H","year":"2012","unstructured":"Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012; 32:1627 - 37; PMID: 22593441","journal-title":"Anticancer Res"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2170-x"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2223-1"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S41786"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.020"}],"container-title":["Translation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/trla.28968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:04:56Z","timestamp":1770905096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4161\/trla.28968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":168,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.4161\/trla.28968"],"URL":"https:\/\/doi.org\/10.4161\/trla.28968","relation":{},"ISSN":["2169-0731"],"issn-type":[{"value":"2169-0731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ktrs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ktrs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28968"}}